about
Ocular inflammation in uveal tract in aged obese type 2 diabetic rats (Spontaneously Diabetic Torii fatty rats)Pharmacotherapy for uveitis: current management and emerging therapy.Review of Systemic Immunosuppression for Autoimmune UveitisAutomated Analysis of Vitreous Inflammation Using Spectral-Domain Optical Coherence TomographyThe immune system in Duchenne muscular dystrophy: Friend or foe.miR-23a, miR-146a and miR-301a confer predisposition to Vogt-Koyanagi-Harada syndrome but not to Behcet's disease.A comprehensive review and update on the biologic treatment of adult noninfectious uveitis: part II.Autoimmune uveitis: clinical, pathogenetic, and therapeutic features.Moving forward in uveitis therapy: preclinical to phase II clinical trial drug development.Non-Infectious Uveitis: Optimising the Therapeutic Response.Review of the ophthalmic manifestations of gout and uric acid crystal deposition.Technology allows detection of target molecules and production of biologic agents for treatment of ocular inflammatory disorders.The promise and limitations of TNF-α inhibition for uveitis.Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation.Optimizing OCT acquisition parameters for assessments of vitreous haze for application in uveitis.[Treatment of posterior noninfectious uveitis : Current situation and future developments].Subretinal Transplantation of Human Amniotic Epithelial Cells in the Treatment of Autoimmune Uveitis in RatsThe Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and Future
P2860
Q34267618-15850842-C54F-4002-B56E-5B9D08987F34Q34274075-F23AED05-EA18-46E2-A7F9-B77628D100ACQ34627012-C37BF0CA-7829-478B-A1D8-928D67E557BEQ36067976-A618193C-F206-4AC4-B398-AECF942F25E7Q36105761-E3811962-1DBB-4179-8C3C-BBB65227BACBQ36512305-72878263-1AC6-45D5-907F-1A710745F5B4Q38250103-0E36BDD3-A78D-4A10-B24F-8BC61FB78311Q38395263-5D21D98C-A5F2-4A45-8057-578762682AE2Q38660708-3D9981B6-7548-4143-92C4-D6572D79B767Q38662045-C577AA38-3505-4894-AE53-EFE160B8C6BAQ38787307-4E77110B-FA3B-48EF-86A4-CDF73A5EC184Q40444244-1886CB40-06FF-493D-BC9D-247754830F3EQ46124138-CB176877-8E23-4D14-8AEF-4F2164D0F67FQ47442388-B6B66AE4-EFC3-4717-990C-6BEDCD390F4CQ49479819-DAE9D0D3-13C4-4A01-8383-AB9E61E06644Q52852545-761BD559-817E-4F4E-A60E-54FAEAA13C63Q57071521-CD8810F9-0A89-4A53-BED9-5E5067D383C1Q58567074-99BB7249-95AD-474C-9E49-AFF5ACA724D5
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The future of uveitis treatment
@en
The future of uveitis treatment.
@nl
type
label
The future of uveitis treatment
@en
The future of uveitis treatment.
@nl
prefLabel
The future of uveitis treatment
@en
The future of uveitis treatment.
@nl
P2093
P2860
P1433
P1476
The future of uveitis treatment
@en
P2093
Eric B Suhler
James T Rosenbaum
Phoebe Lin
P2860
P304
P356
10.1016/J.OPHTHA.2013.08.029
P577
2013-10-26T00:00:00Z